Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25028929 | 0.76 | NOS3 (0.39) | MAPK14MAOBKDM4EHSD17B10AHR | |
| SCHEMBL5395605 | 0.73 | F2RL3 (0.42) | MAPK14F2RL3KDM4EAHRSCN5A | |
| SCHEMBL6601087 | 0.72 | TP53 (0.44) | KDM4EHSD17B10 | |
| SCHEMBL25371122 | 0.72 | MAPK14 (0.35) | MAPK14MAOBKDM4EHSD17B10AHR | |
| SCHEMBL17252261 | 0.71 | MARS1 (0.41) | CYP1A2KDM4EHSD17B10 | |
| SCHEMBL22361048 | 0.71 | GABRA2 (0.35) | MAPK14 | |
| SCHEMBL25027517 | 0.70 | MAP4K4 (0.56) | CYP1A2KDM4E | |
| SCHEMBL3186083 | 0.70 | MAPK14 (0.47) | MAPK14CYP1A2F2RL3GAAKDM4E | |
| SCHEMBL25220159 | 0.69 | KIF11 (0.38) | MAPK14KDM4EHSD17B10AHRSCN5A | |
| SCHEMBL6599132 | 0.69 | TRPA1 (0.43) | MAPK14AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619402-A1 | GPR17 MODULATORS AND USES THEREOF | Myrobalan Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| CN-119613397-A | N-heteroaromatic ring-3-sulfonamide compounds and use thereof for preparing GPR17 receptor inhibitors | 迈巴制药(南京)有限公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2024104462-A1 | GPR17 MODULATORS AND USES THEREOF | MYROBALAN THERAPEUTICS NANJING CO. LTD (CN) | 2024-05-23 | — | — | WO | disclosed |